Urokinase prophylactic anticoagulation in children with nephrotic syndrome: a multicenter retrospective cohort study

Table 2 Clinical features in the different phases of PNS

	Clinical phase	UK	Non-UK	P-value
Median serum albumin (g/L)	acute phase	20.1 ± 5.1	21.8 ± 5.9	0.02
Median serum albumin (g/L)	remission or partial remission phase	29.2 ± 5.4	30.3 ± 4.3	0.31
Median serum cholesterol (mmol/L)	acute phase	10.7 ± 3.0	10.9 ± 3.0	0.63
Median serum cholesterol (mmol/L)	remission or partial remission phase	7.2 ± 2.3	6.6 ± 1.4	0.03
Median serum triglyceride (mmol/L)	acute phase	2.9 ± 2.1	2.8 ± 1.8	0.90
Median serum triglyceride (mmol/L)	remission or partial remission phase	2.2 ± 1.3	1.8 ± 1.1	0.02
Median serum urea nitrogen(mmol/L)	acute phase	4.7 ± 3.0	5.1 ± 1.9	0.34
Median serum urea nitrogen(mmol/L)	remission or partial remission phase	4.0 ± 1.3	4.1 ± 1.2	0.57
Median serum creatinine (µmol/L)	acute phase	35.6 ± 17.3	34.4 ± 18.6	0.64
Median serum creatinine (µmol/L)	remission or partial remission phase	31.9 ± 11.7	34.6 ± 10.4	0.11

ISSN: 1471-2369